Skip to main content
. 2022 Jun 7;33(2):166–171. doi: 10.1007/s13337-022-00766-y

Table 2.

Seroprevalence estimates of SARS-CoV-2 antibodies along with the associated variables

Characteristics Tested (N) Tested (%) Positive (n) Seroprevalence (%) Seroprevalence (95% CI) p-value
Gender 3077 100.0 2279 74.1 72.5, 75.6 NA
Females 599 19.5 418 69.8 66.0, 73.3 < 0.010
Males 2478 80.5 1861 75.1 73.4, 76.8
Age group (years)
18–39 1854 60.3 1417 76.4 74.4, 78.3 < 0.001
40–59 1209 39.3 853 70.6 67.9, 73.1
Official rank
Officers 298 9.7 190 63.8 58.2,69.0 < 0.001
Non-officers 2779 90.3 2089 75.2 73.5, 76.7
Medical comorbid condition/s
No 2549 82.8 1911 75.0 73.3, 76.6 < 0.005
Yes 528 17.2 368 69.7 65.6, 73.5
Any resident member had COVID-19
No 2866 93.1 2090 72.9 71.3, 74.5 < 0.001
Yes 211 6.9 189 89.6 84.7, 93.1
COVID-19 diagnosed earlier
No 2258 73.4 1497 66.3 64.3, 68.2 < 0.001
Yes 819 26.6 782 95.5 93.8, 96.7
COVID-19 RT PCR result earlier
Negative 1552 50.4 1048 67.5 65.2, 69.8 < 0.001
Positive 643 20.9 620 96.4 94.7, 97.6